GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Other Financing Activities

Financing cash flows not reported separately.

GSK plcNYSE: GSK

Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026

Other financing activities turns negative

Q2 FY2026 other financing activities was -£228.03M, compared with £342M a year earlier. Trailing-twelve-month other financing activities was £448.71M.

Context

  • Other financing activities amounted to 1.8% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other financing activities holds near -£228.03M or moves back toward the trailing-twelve-month quarterly average of £112.18M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-£228.03M-547.1% QoQ
Last fiscal yearDec 2025
-£573.16M-49.5% YoY
LTMJun 2026
£448.71M+205.3% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-166.7%——
1 year-49.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

GBP · from the cash flow

Latest · FY2025
(573.16M) GBP
Year-over-year change
+49.5%

Other Financing Activities vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +205.3% is the 2nd highest of 9, against a peer median of -21.3%.
  • Other financing activities amounts to 1.4% of revenue for GSK, versus a peer median of 0.6%.
GSK Competitors
Other Financing Activities for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNYSanofiLTM Jun 2026€5.42B EUR+815.0%+62.1%11.1%
NVONovo Nordisk A/SLTM Jun 2026DKK 2.76B DKK——0.8%
LLYEli Lilly and CompanyLTM Jun 2026$650.3M USD-19.7%+35.7%0.8%
JNJJohnson & JohnsonLTM Sep 2026$625M USD-206.5%+31.3%0.6%
GSKGSK plcLTM Jun 2026£448.71M GBP+205.3%—1.4%
PFEPfizer Inc.LTM Jun 2026$392M USD-1.0%+11.1%0.6%
AZNAstraZeneca PLCLTM Sep 2026$338.64M USD+37.8%-30.0%0.5%
NVSNovartis AGLTM Jun 2026$259.61M USD-23.0%—0.5%
MRKMerck & Co., Inc.LTM Jun 2026$227M USD-25.3%-18.3%0.3%
AMGNAmgen Inc.LTM Jun 2026$157M USD-96.4%-20.4%0.4%
Peer median (excluding GSK) —-21.3%+11.1%0.6%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.52B5.49B6.13B2.95B5.59B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
Deferred Income Tax0(965.72M)(1.08B)00
Stock-Based Compensation343M00344M0
Change in Working Capital1.39B(1.67B)(1.06B)2.09B(608.37M)
Accounts Receivables(1.16B)(758.78M)(806.74M)340M0
Inventory51M(331.35M)(527.05M)(294M)0
Accounts Payables0608.5M(18.65M)00
Other Working Capital2.5B(1.19B)288.39M2.04B(608.37M)
Other Non-Cash Items584M3.16B1.61B(1.38B)(153.41M)
Operating Cash Flow7.95B8.16B7.89B6.55B7.14B
Capital Expenditures(2.65B)(1.41B)(1.63B)(2.98B)(1.32B)
Acquisitions (Net)185M(3.79B)(1.72B)1.37B(4.37B)
Purchases of Investments0(177.38M)(152.9M)0(89.98M)
Sales of Investments18M294.4M2.37B21M195.62M
Other Investing Activities(1.03B)(4.43B)14.92M(1.22B)1.46B
Investing Cash Flow(1.78B)(10.88B)(2.4B)(1.23B)(5.72B)
Debt Repayment(2B)(5.69B)(2.95B)(1.17B)1.47B
Common Stock Issued21M30.79M12.43M20M14.67M
Common Stock Repurchased00000
Dividends Paid(4B)(4.27B)(2.79B)(2.44B)(2.51B)
Other Financing Activities(1.61B)11.98B(341.84M)(1.14B)(573.16M)
Financing Cash Flow(7.59B)2.05B(6.07B)(4.73B)(1.59B)
Effect of Forex Changes(29M)(637.97M)(153.84M)(54M)(32.94M)
Net Change in Cash(1.44B)(1.31B)(735.58M)545M(206.06M)
Free Cash Flow5.3B6.75B6.26B3.57B5.82B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.